Completion of clinical trial Specified Successful | fostamatinib
Item
patients who have successfully completed a qualifying study (d4300c00001, d4300c00002, d4300c00003 or d4300c00004) with fostamatinib
boolean
C2732579 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
C1272703 (UMLS CUI [1,3])
C2713632 (UMLS CUI [2])
Participation Clinical Trials Specified | Therapy non-responder Due to Lack of Efficacy
Item
patients who have participated in a qualifying study and who have been classified as non-responders due to pre-defined lack of efficacy at week 12 (d4300c00001, d4300c00002, d4300c00003).
boolean
C0679823 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0205369 (UMLS CUI [1,3])
C0919875 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0235828 (UMLS CUI [2,3])
Patient withdrawn from trial specified
Item
premature withdrawal from the qualifying study (d4300c00001, d4300c00002, d4300c00003 and d4300c00004)
boolean
C0422727 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
females who are pregnant or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Poor hypertension control
Item
poorly controlled hypertension
boolean
C0421190 (UMLS CUI [1])
Liver function tests abnormal | Physical symptom Hepatotoxicity
Item
significant liver function test abnormalities or physical symptoms of hepatotoxicity
boolean
C0151766 (UMLS CUI [1])
C0679309 (UMLS CUI [2,1])
C0235378 (UMLS CUI [2,2])
Communicable Disease
Item
significant infection
boolean
C0009450 (UMLS CUI [1])
Gastrointestinal sensitivity (hyper)
Item
gastrointestinal intolerance
boolean
C1533260 (UMLS CUI [1])
Malignant Neoplasms
Item
cancer
boolean
C0006826 (UMLS CUI [1])